Article | February 14, 2024

Big Risks Yield Great Rewards In Cell Therapy

Source: Cytiva

Similar to the pioneers who explored new territories, early advocates of cell therapy bravely navigated through uncertainty to pave the way for patients. To explore this journey further, we had the privilege of speaking with George White, Cytiva’s General Manager of Product Management for Cell and Gene Therapy. In our conversation, White sheds light on the role of risk in transforming cell therapies from mere dreams into life-saving treatments, while also contemplating the challenges that lie ahead as these therapies progress towards wider adoption and becoming the standard of care.

Noted during this discussion, was the crucial role clinical trials play in advancing cell therapy, as they provide evidence of safety and efficacy. However, conducting clinical trials for cell therapies can be complex and time-consuming, requiring careful planning and execution. Furthermore, the regulatory landscape for cell therapy is constantly evolving, with new guidelines and requirements being introduced. Companies and researchers need to stay up-to-date with these regulations to ensure compliance and successful product development.

Despite the risks and uncertainties, the potential to revolutionize medicine and improve patient outcomes is driving the industry forward. Accessing the full version of this article will provide readers with a comprehensive understanding of the latest developments and strategies in cell therapy, as well as insights into the future direction of this dynamic field.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development